Advertisement
ALNY or BMY or IONS
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Bristol-Myers Squibb (BMY) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- ALNY leads YTD performance at +19.42%, driven by RNAi therapeutic advancements and partnerships, with a market cap of $42.5B.
- BMY offers stability with a 4.27% dividend yield and YTD gain of +10.45%, supported by its diversified biopharma portfolio and $120B market cap.
- IONS shows strong 1-year return of +110.87% but remains unprofitable, focusing on RNA-targeted pipeline catalysts like olezarsen priority review.
- All three exhibit low betas (0.27-0.38), indicating reduced volatility compared to the broader market.
- BMY trades at the lowest trailing P/E of 17.02, contrasting with high-growth biotech valuations for ALNY (136.93) and IONS (N/A).
- Recent momentum favors ALNY and IONS amid biotech pipeline news, while BMY provides income reliability.
Introduction
This comparison examines ALNY, BMY, and IONS, three biopharma stocks with exposure to innovative RNA-based therapies and broader oncology/cardiovascular portfolios. ALNY and IONS specialize in RNAi and antisense technologies targeting rare genetic diseases, while BMY offers a diversified large-cap profile. Traders seeking growth amid biotech catalysts and investors prioritizing stability with dividends will find value in analyzing their relative performance, valuations, and market positioning in the current environment.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) is a leader in RNA interference (RNAi) therapeutics, developing drugs like ONPATTRO, AMVUTTRA, and GIVLAARI for rare diseases such as hATTR amyloidosis and acute hepatic porphyria. In recent market activity, ALNY shares have traded around $320, with a market cap of $42.5B and YTD return of +19.42%, outperforming the S&P 500's +1.89%. Sentiment has been bolstered by partnerships, including a $1.23B deal with Tenaya Therapeutics for cardiovascular RNAi targets and a multi-year precision medicine agreement with Helix. Despite a high trailing P/E of 136.93 and low beta of 0.38, recent weeks saw modest gains amid analyst price targets averaging $457, reflecting pipeline optimism despite share price weakness earlier in the quarter.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharma giant focused on oncology, immunology, and cardiovascular therapies, with key products like Opdivo, Eliquis, and Revlimid generating $48B in trailing revenue. Shares hover near $59, with a $120B market cap and YTD performance of +10.45%, ahead of the S&P 500. Recent activity reflects stability, supported by Q4 growth portfolio gains and CELMoD program Phase III success, alongside a forward P/E of 9.58 and attractive 4.27% dividend yield. Low beta (0.27) underscores defensive positioning, with analyst targets at $62.36 amid pipeline momentum in immunotherapy, though legacy drug pressures linger. Market sentiment remains steady in recent weeks.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) pioneers RNA-targeted medicines, including SPINRAZA, TEGSEDI, and emerging assets like DAWNZERA for hereditary angioedema and WAINUA for ATTRv-PN. Trading around $72 with an $11.9B market cap, IONS posted a YTD return of +8.57% and exceptional 1-year gain of +110.87%. Recent sentiment shifts positively on FDA priority review for olezarsen in severe hypertriglyceridemia and new DAWNZERA data, alongside Board changes. Despite losses (EPS -2.38) and high debt/equity, a beta of 0.36 and $94 analyst target highlight growth potential from Phase 3 catalysts, with shares stable in recent trading.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from deep learning and price action analysis to multi-agent systems—operating on timeframes like 5min, 15min, and 60min, with risk levels from low to high. Selected from over 351 total bots, the trending section highlights 25+ standouts engineered for current market conditions, delivering annualized returns up to 279% in recent periods, win rates exceeding 90% in top performers, and profit factors around 2.5. While biotech-specific bots are not featured, the variety suits growth-oriented traders. Explore these AI tools for data-driven signals tailored to volatile sectors like pharma.
Head-to-Head Comparison
ALNY, BMY, and IONS operate in biopharma but diverge in models: ALNY and IONS emphasize high-risk RNAi/antisense innovation for rare diseases, while BMY balances growth via diversified blockbusters. Growth drivers include ALNY's partnerships and IONS's regulatory nods versus BMY's steady revenue. Recent momentum favors ALNY (1-month +5.91%) over BMY's flatness, with all low-beta profiles mitigating volatility. Risks: biotech pipeline delays for ALNY/IONS versus BMY's patent cliffs. Valuation sensitivity shows BMY's attractive multiples (P/E 17, P/S 2.53) against elevated biotech ratios; sentiment tilts growth-positive for RNAi plays amid sector catalysts.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY for its superior trend consistency, YTD outperformance, and pipeline catalysts like recent partnerships, positioning it strongly relative to peers. IONS offers high-upside potential probabilistically via regulatory momentum, while BMY suits stability seekers. Observable factors like low volatility and analyst upside suggest ALNY edges in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s), and IONS’s FA Score reflects 0 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- BMY’s FA Score: 2 green, 3 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s), and IONS’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 6 bearish.
- BMY’s TA Score: 4 bullish, 6 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -6.62% price change this week, while BMY (@Pharmaceuticals: Major) price change was +1.84% , and IONS (@Biotechnology) price fluctuated -0.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +11.85%, and the average quarterly price growth was +11.50%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.06%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was +7.76%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
BMY is expected to report earnings on Apr 30, 2026.
IONS is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Biotechnology (+4.27% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+2.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ALNY | BMY | IONS | |
| Capitalization | 41.5B | 121B | 12.4B |
| EBITDA | 631M | 15.2B | -273.12M |
| Gain YTD | -21.806 | 12.061 | -5.360 |
| P/E Ratio | 133.45 | 17.09 | N/A |
| Revenue | 3.71B | 48.2B | 944M |
| Total Cash | 2.91B | N/A | 2.68B |
| Total Debt | 1.28B | 47.1B | 2.07B |
ALNY | BMY | IONS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 6 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 39 Fair valued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 52 | 82 | 45 | |
SMR RATING 1..100 | 15 | 23 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | 21 | 41 | |
P/E GROWTH RATING 1..100 | 100 | 70 | 76 | |
SEASONALITY SCORE 1..100 | 50 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALNY (94) in the Biotechnology industry, and is somewhat better than the same rating for IONS (100) in the Biotechnology industry. This means that BMY's stock grew somewhat faster than ALNY’s and somewhat faster than IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (45) in the Biotechnology industry is in the same range as ALNY (52) in the Biotechnology industry, and is somewhat better than the same rating for BMY (82) in the Pharmaceuticals Major industry. This means that IONS's stock grew similarly to ALNY’s and somewhat faster than BMY’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as BMY (23) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that ALNY's stock grew similarly to BMY’s and significantly faster than IONS’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as IONS (41) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (62) in the Biotechnology industry. This means that BMY's stock grew similarly to IONS’s and somewhat faster than ALNY’s over the last 12 months.
BMY's P/E Growth Rating (70) in the Pharmaceuticals Major industry is in the same range as IONS (76) in the Biotechnology industry, and is in the same range as ALNY (100) in the Biotechnology industry. This means that BMY's stock grew similarly to IONS’s and similarly to ALNY’s over the last 12 months.
| ALNY | BMY | IONS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 48% | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 50% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 53% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 47% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 52% | 1 day ago 66% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 54% | 1 day ago 74% |
| Advances ODDS (%) | 8 days ago 76% | 5 days ago 54% | 7 days ago 66% |
| Declines ODDS (%) | 5 days ago 66% | 9 days ago 53% | 9 days ago 65% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 45% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 55% | 1 day ago 75% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OND | 36.56 | 2.32 | +6.78% |
| ProShares On-Demand ETF | |||
| RIET | 9.71 | 0.01 | +0.10% |
| Hoya Capital High Dividend Yield ETF | |||
| ZJUN | 27.26 | -0.01 | -0.02% |
| Innovator Equity Dfnd Prot ETF -1 YrJune | |||
| FISR | 25.86 | -0.02 | -0.10% |
| State Street® Fixed Inc Sect RotationETF | |||
| VOX | 197.50 | -1.55 | -0.78% |
| Vanguard Communication Services ETF | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | -1.73% | ||
| PFE - BMY | 63% Loosely correlated | -0.15% | ||
| MRK - BMY | 60% Loosely correlated | -1.65% | ||
| AMGN - BMY | 58% Loosely correlated | -1.45% | ||
| BIIB - BMY | 54% Loosely correlated | +3.38% | ||
| ABBV - BMY | 54% Loosely correlated | -2.24% | ||
More | ||||
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been closely correlated with CYTK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | -1.11% | ||
| CYTK - IONS | 66% Closely correlated | -0.85% | ||
| MLYS - IONS | 66% Loosely correlated | -1.64% | ||
| MNKD - IONS | 49% Loosely correlated | +2.64% | ||
| IDYA - IONS | 47% Loosely correlated | -1.03% | ||
| ARWR - IONS | 46% Loosely correlated | -0.37% | ||
More | ||||